New Service One Sheet: Strategic Consulting

Posted by Fuld + Company

Feb 10, 2016 1:59:50 PM

War Gaming and Scenario Planning are essential tools when laying the groundwork of a company's strategy. These activities uncover threats and opportunities presented by the external environment. They help role-play the competition, revealing weaknesses that may not be visible from an internal perspective. They break participants out of rote patterns of thought, forcing confrontation with shifting markets or disruptive technologies. They stress-test existing strategy and suggest new courses of action.

To piece together the insights gained by these tools into a cohesive plan, whether starting from scratch or adapting existing strategy, is no easy task. There are many stakeholders to consider, from senior leaders to working-level professionals, and tough choices to be made. Too often, strategic planning can be a disappointing process.

Read More

Topics: Fuld + Company, Competitive Strategy

Upcoming Event: Fuld + Co. at Pharma CI Europe 2016 Conference & Exhibition

Posted by Fuld + Company

Feb 1, 2016 10:17:25 AM

Join us this month at Pharma CI Europe Conference & Exhibition taking place February 18-19th at the Charles de Gaulle Airport Marriott Hotel in Paris, France.

The Pharma CI Conference & Exhibition is the largest assembly of senior level pharma, biotech, and device professionals seeking the latest news and the chance to network with all the industry’s luminaries. 

Members of our Life Sciences team will be at our booth to find out how we can address your competitive intelligence and strategy development needs in the pharmaceutical, biotech, medical device, and diagnostics industries. David Staknis, Ph.D., Principal, Global Life Sciences Practice Head will be giving a talk on Protecting Institutional CI Memory on Friday, February 19th (details after the jump). 

Read More

Topics: Competitive Intelligence, Events, Fuld + Company, Life Sciences, Competitive Strategy

Leonard Fuld in HBR: Only Half of Companies Actually Use the Competitive Intelligence They Collect

Posted by Fuld + Company

Jan 28, 2016 2:50:55 PM

In his most recent Harvard Business Review article, charman and founder Leonard Fuld joins Ben Gilad, president and co-founder of the Fuld-Gilad-Herring Academy of Competitive Intelligence (ACI), to assess the impact of CI on major company decisions.

Based on a survey of 236 CI managers and analysts across 21 industries, Fuld and Gilad found that 55% of respondents said "their input on major management decisions made enough difference to improve the decision," leaving 45% whose analysis was ineffective at influencing executive decision making. 

When CI analysts were effective, four variables played a significant role: 

Read More

Topics: Competitive Intelligence, FGH Academy of Competitive Intelligence, Fuld, Leonard, Competitive Strategy

Medical Education and the Affordable Care Act

Posted by Fuld + Company

Jan 28, 2016 10:32:17 AM

Ken Sawka   | Jacob Golbitz 

Perhaps it was inevitable. Kaiser Permanente, the California-based health system that integrates health insurance with its own hospitals and clinics, last month announced that it would open its own medical school in the state in 2019. 

The move underscores two factors that have bedeviled healthcare reform in the United States before and after the passage of the Affordable Care Act in 2010 – a forecasted shortage of physicians in the United States, and the failure of traditional medical education to keep pace with the training required to enable physicians to provide healthcare in an integrated, risk-based system.

Read More

Topics: Competitive Intelligence, Innovation, Market Analysis, Healthcare, Life Sciences

Uber's Airbus Helicopter Partnership Flies Close to the Sun

Posted by Nathaniel Emmons

Jan 26, 2016 8:00:00 AM

It’s raining. Traffic is backed-up and not moving. Take out your smartphone and summon an Uber. An Uber helicopter that is.

Uber has hovered around the aviation sector for the past few years, offering helicopter rides from Manhattan to the Hamptons and flights to Coachella. Last weekend the firm announced it was partnering with Airbus to provide on-demand helicopter services for the Sundance Film Festival in Park City, Utah. Local authorities have tried to shut down the service this weekend, but what spurred the partnership in the first place?

Read More

Topics: Brand Insights, Innovation, Technology/Telecomm, Competitive Strategy

Is the Chevrolet Bolt a Tesla-Killer?

Posted by Christopher Dent

Jan 14, 2016 1:34:32 PM

The Chevrolet Bolt

Tesla has been synonymous with electric cars for nearly a decade. Sleek, forward-thinking, high-end: that’s the Tesla we know today. Still, from the inception of the Tesla Roadster, CEO Elon Musk has insisted that Tesla’s strategic end-goal is to one day create a “super affordable electric vehicle with mass market appeal.  

That day has finally come. But it’s not Tesla holding the prize. 

Read More

Topics: Brand Insights, Market Analysis, Product Positioning, Competitive Strategy

Filgotinib: Still Early to Pop the Champagne

Posted by Adi Reske

Dec 24, 2015 12:38:39 PM

Recently, Galapagos NV and Gilead entered a partnership, potentially worth more than $2 billion, to develop Galapagos’s oral JAK1 inhibitor, filgotinib, for inflammatory diseases.

Earlier in December 2015, Galapagos announced positive interim Phase II Crohn’s disease results for filgotinib. Based on the data presented, 48% of moderate to severe CD patient treated with filgotinib achieved clinical remission at 10 weeks compared to 23% placebo (p=0.0067); clinical response (CDAI decrease of 100 points or more) as well improvement in patients’ quality of life were also met in the study. According to the company’s CEO, results from the Phase II trial merit moving the drug into a Phase III Crohn's program “as soon as possible”.

Read More

Topics: Brand Insights, Pharma, Life Sciences, Product Positioning

New Video! Building a Life Sciences CI Team

Posted by Fuld + Company

Dec 15, 2015 9:50:08 AM

Finding the right talent to fill CI needs at a Life Sciences company can be challenging. From companion diagnostics to biosimilars, it's a complex marketplace that requires highly skilled CI practitioners.

David Staknis, Principal, Practice Head Global Life Sciences, and Ken Sawka, CEO + President, discuss necessary industry experience and academic qualifications for inclusion in a CI team, as well as team dynamics within Fuld + Company's own Life Sciences practice.

Read More

Topics: Competitive Intelligence, Fuld + Company, Pharma, Healthcare, Life Sciences

Fuld + Company and Agromeris Partner to Expand Services for Food and Agriculture Industry

Posted by Fuld + Company

Dec 14, 2015 8:00:00 AM


FOR IMMEDIATE RELEASE

BOSTON, MA, December 14, 2015 -- Fuld + Company, a competitive intelligence, strategy, and consulting firm, announced that it has signed a memorandum of understanding with Agromeris, a food and agriculture consulting firm.

The partnership provides Agromeris with methodological expertise and research capacity, drawn from Fuld + Company's 35+ years of experience. Agromeris brings to the partnership 30 years of deep domain expertise across the entire food production value chain, from field to table.

Read More

Topics: Competitive Intelligence, Consumer Goods, Fuld + Company, Manufacturing/Industrial, Market Analysis, Scenario Analysis, Product Positioning, Competitive Strategy

New Video! Companion Diagnostics

Posted by Fuld + Company

Dec 11, 2015 8:00:00 AM

Companion diagnostic (CDx) devices are in vitro and imaging tools that are paired with specific drug therapies. Part of a larger trend towards personalized medicine, they are used to identify patients most likely to benefit from a specific therapeutic agent or to determine appropriate dosage. 

While questions remain about who should bear the cost for companion diagnostics, the promise of greater safety and efficacy and the potential for faster regulatory approval have made this an area of growth for both pharmaceutical and molecular diagnostics clients.

David Staknis, Principal, Practice Head Global Life Sciences, and Ken Sawka, CEO + President, discuss increased requests for monitoring development and expansion of CDx platforms, earlier coordination by pharmaceutical and diagnostics firms, and the benefits of CI for optimizing R&D spending.

Read More

Topics: Competitive Intelligence, Early Warning Monitoring, Medical Devices, Pharma, Healthcare, Life Sciences

Fuld + Company Blog

The material on this page draws on the research and experience of Fuld + Company thought leaders, consultants and others. Learn more about our expertise here.

Request for Information

If you'd like someone at Fuld to contact you regarding your strategic competitive challenges, fill out the form below.